Singapore, Nov. 24 -- Sanofi and AstraZeneca's Beyfortus (Nirsevimab) is now approved by the National Pharmaceutical Regulatory Agency(NPRA) and is available for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants born during or entering their first RSV season.

RSV is predominantly seen in infants less than 1 year old and infected children below 2 years old had a high hospitalisation rate of 84.5%. As a tropical climate country, RSV circulation in Malaysia is seen throughout the year with distinct peaks.

The approval was based on results from the extensive Beyfortus clinical development programme spanning across broad infant population from pre-term, heathy full-term and those with...